Find the latest Akero Therapeutics, Inc., AKRO stock market data. 50-Day Range $20.75 $26.24. Learn more about MarketBeat. Total operating expenses were $29.0 million for the three-month period ended June 30, 2021, compared to $16.5 million for the comparable period in 2020. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. Market Capitalization . This page features the latest news about the Akero Therapeutics stock. Investor Contact:Christina Tartaglia212.362.1200[email protected], Media Contact:650.487.6488[email protected], Akero Therapeutics Reports Second Quarter 2021 Financial Results and Provides Business Update, Cash, cash equivalents and short-term marketable securities, Total liabilities and stockholders’ equity, Condensed Consolidated Statements of Operations and Comprehensive Loss, (In thousands, except share and per share amounts), Net loss per common share, basic and diluted, Weighted-average number of shares used in computing net loss per common share, basic and diluted. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements, including, but not limited to, statements regarding Akero's business plans and objectives, including future plans or expectations for EFX, upcoming milestones, and therapeutic effects of EFX, as well as the dosing, safety and tolerability of EFX; Akero’s Phase 2b HARMONY and Phase 2b SYMMETRY clinical trials; the Fast Track designation of EFX, potential benefits resulting from such designation and related implications; and the potential impact of COVID-19 on strategy, future operations, enrollment and clinical trials. The Fast Track designation facilitates the development of new drugs to treat serious conditions where there is an unmet medical need.
New Stories. Cash, cash equivalents and short-term marketable securities Get short term trading ideas from the MarketBeat Idea Engine. SOUTH SAN FRANCISCO, Calif., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (NASDAQ:AKRO), a clinical-stage company developing transformational treatments for patients with serious . Sign up to receive the latest news and ratings for AKRO and its competitors with MarketBeat's FREE daily newsletter. All forward-looking statements contained in this press release speak only as of the date on which they were made.
We began with an engineered protein called efruxifermin (EFX), which we licensed from Amgen and are developing for treatment of non-alcoholic steatohepatitis (NASH).
Get Akero Therapeutics Inc (AKRO:NASDAQ) real-time stock quotes, news, price and financial information from CNBC. This volume reports on how these substances work in the animals' metabolism, what effects they might have on nutrient requirements of domestic livestock, and what information should be developed further by investigators. Filed by: venBio Global Strategic Fund, L.P. View All Articles Aug 12, 2019 07:14 AM Akero Therapeutics (AKRO) Misses Q2 EPS by 185c Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. Securities trading is offered to self-directed customers by Webull Financial LLC, a broker dealer registered with the Securities and Exchange Commission (SEC). Get the latest Akero Therapeutics Inc (AKRO) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions.
7 Precious Metals Stocks That Will Offset the Effects of Inflation, 7 E-Commerce Stocks That Aren’t Tangled in the Supply Chain, 7 Electric Vehicle Stocks That Are Ready to Charge Higher, 7 Social Media Stocks That Are Worth Your Attention, 7 Trucking Stocks That Are About to Go On a Roll, 7 Pharmaceutical Stocks to Buy For a Healthy Portfolio in 2022, 7 Growth Stocks to Buy as the Market Slumps, 7 Virtual Reality Stocks That Can Deliver Very Real Profits, 7 Cyclical Stocks That Make Sense In a Volatile Market, 7 Stocks That Can Withstand a Taper Tantrum, Akero Therapeutics (NASDAQ:AKRO) Shares Gap Down to $24.22, Wall Street Analysts Think Akero Therapeutics, Inc. (AKRO) Could Surge 92%: Read This Before Placing a Bet, Akero Therapeutics (NASDAQ:AKRO) Shares Up 5.4% After Better-Than-Expected Earnings, Morgan Stanley Raises Akero Therapeutics (NASDAQ:AKRO) Price Target to $29.00, Akero Therapeutics (NASDAQ:AKRO) Price Target Raised to $49.00, HC Wainwright Trims Akero Therapeutics (NASDAQ:AKRO) Target Price to $62.00, Akero Therapeutics (NASDAQ:AKRO) Issues Quarterly Earnings Results, Akero Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Update, Akero Presents New Analysis of Phase 2a BALANCED Study Data Showing Additional Qualitative Evidence of Histological Improvement in EFX-treated NASH Patients after 16 Weeks of Treatment, Akero Therapeutics to Present at the Jefferies London Healthcare Conference, Akero Therapeutics, Inc. (NASDAQ:AKRO) COO Jonathan Young Sells 18,780 Shares, Akero Therapeutics, Inc. (NASDAQ:AKRO) Given Average Rating of "Buy" by Brokerages, Akero Therapeutics Reports Received FDA Fast Track Designation For Efruxifermin For Treatment Of NASH, Akero Therapeutics’ NASH Treatment Gets Fast Track Designation; Shares Rise, Akero Therapeutics Receives FDA Fast Track Designation for Efruxifermin (EFX) for the Treatment of NASH, Akero Therapeutics to Present at the H.C. Wainwright 5th Annual NASH Investor Conference, Akero Therapeutics (NASDAQ:AKRO) Is In A Good Position To Deliver On Growth Plans, Here's Why We're Not Too Worried About Akero Therapeutics' (NASDAQ:AKRO) Cash Burn Situation, Akero Therapeutics to Present at the Morgan Stanley Virtual Global Healthcare Conference, Akero Therapeutics Reports Second Quarter 2021 Financial Results and Provides Business Update, Akero Therapeutics Inc Shares Near 52-Week Low - Market Mover, Akero's NASH Candidate Shows Substantial Liver Fat Reductions After Four Months Of Treatment, Study Published in Nature Medicine Shows Investigational NASH Drug Reduced Liver Fat to Normal Levels and Reversed Fibrosis After 16 Weeks of Treatment, Akero Therapeutics Presents at the American Diabetes Association’s 81st Scientific Sessions, Demonstrating that Improvements in Adipose Tissue Metabolism Contributed Substantially to Improved Liver Health and Better Glycemic Control in Efruxifermin (EFX)-treated Pre-Cirrhotic NASH Patients, Akero Therapeutics New Analyses For Efruxifermin Shows Rapid, Substantial Liver Fat Reduction In NASH Patients, Akero Therapeutics Presents Analyses at the 2021 International Liver Congress Showing Normalization of Liver Fat Substantially Reduced Markers of Liver Injury and Fibrosis, and Greatly Increased Probability of Resolving NASH, Akero Therapeutics Breaks Above 200-Day Moving Average - Bullish for AKRO. Its lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regulates . Akero is a clinical-stage company founded to develop transformational treatments for patients with serious metabolic diseases marked by high unmet medical need. Akero Therapeutics Reports Third Quarter 2021 Financial ... Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. Volume today is 208,726 compared to average volume of 264,713. Jobs with Akero Therapeutics - biospace.com
© American Consumer News, LLC dba MarketBeat® 2010-2021. In a report released today, Matthew Harrison from Morgan Stanley maintained a Hold rating on Akero Therapeutics (AKRO - Research Report), with a price target of $29.00.The company's shares closed last Monday at $26.36. Akero Therapeutics Inc is a clinical-stage biotechnology . by Zacks Equity Research Published on April 06,2020. View real-time stock prices and stock quotes for a full financial overview. SOUTH SAN FRANCISCO, Calif., Aug. 13, 2021 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a cardio-metabolic biotechnology company developing transformational treatments for non-alcoholic steatohepatitis (NASH), today reported second quarter financial results for the period ending June 30, 2021. SOUTH SAN FRANCISCO, Oct. 19, 2021 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a cardio-metabolic biotechnology company developing transformational treatments for non-alcoholic steatohepatitis (NASH), today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to its lead program investigating efruxifermin (EFX) for the treatment of non-alcoholic steatohepatitis (NASH). Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock.
AKRO: Get the latest Akero Therapeutics stock price and detailed information including AKRO news, historical charts and realtime prices. Akero's cash, cash equivalents and short-term marketable securities for the period ended June 30, 2021 were $230.0 million. We track news headlines from hundreds of news outlets and tag them by company. “Our clinical and manufacturing momentum is a testament to our confidence in efruxifermin (EFX), which has the potential to be among the first investigational NASH therapies approved for treatment of both pre-cirrhotic (F2/F3) and cirrhotic (F4) NASH,” said Andrew Cheng, M.D., Ph.D., president and chief executive officer of Akero. Akero Therapeutics, Inc. (AKRO) might move higher on growing optimism about its . SOUTH SAN FRANCISCO, Oct. 19, 2021 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a cardio-metabolic biotechnology company developing transformational treatments for non .
These increases are attributable to higher costs related to Akero's EFX program, including third-party contract manufacturing, contract research organization costs associated with the BALANCED and HARMONY studies and internal personnel costs. The company's product candidate efruxifermin is an FGF21 analog with properties . Akero Therapeutics, Inc. Common Stock (AKRO) Nasdaq 6/25/2021. According to TipRanks.com, Harrison is a 5-star analyst with an average return of 14.7% and a 56.2% success rate. Akero Therapeutics Inc (AKRO) stock is trading at $25.81 as of 2:46 PM on Tuesday, Jun 29, a loss of -$1.45, or -5.32% from the previous closing price of $27.26.
Get the latest stock news for Nasdaq companies, press releases, financial disclosures and multimedia content, for day traders, investment community, individual investors and the general public. Investor Contact: Christina Tartaglia Stern Investor Relations, Inc. 212.362.1200christina.tartaglia@sternir.com, Media Contact: 650.487.6488 media@akerotx.com. "Our team remains focused on successfully completing two Phase 2b clinical trials . Learn about financial terms, types of investments, trading strategies and more.
Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. Latest Tango Therapeutics Inc (TNGX:NMQ) share price with interactive charts, historical prices, comparative analysis, forecasts, business profile and more.
What Makes Akero Therapeutics, Inc. (AKRO) a New Buy Stock. Akero Therapeutics announced results of a 16-week analysis of secondary and exploratory endpoints in its Phase 2a BALANCED study of efruxifermin (EFX), formerly known as AKR-001, in patients with nonalcoholic steatohepatitis (NASH).. Average Volume 228,873 shs. Akero Therapeutics news and AKRO price. by Zacks Equity Research Published on April 06,2020. The stock has traded between $25.70 and $27.34 so far today.
Akero undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made. These books also boast the masterful prose, unsurpassed evocations of the Southwest, and fascinating insights into Navajo culture that have made Tony Hillerman so enormously popular. All news about AKERO THERAPEUTICS, INC. 07:34a: AKERO THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition a.. AQ.
That means it scores higher than 48 percent of stocks. Find the latest Akero Therapeutics, Inc financial news and headlines to keep up with the events that impact AKRO performance. That means it scores higher than 54 percent of stocks. 10/11/2021 14:05:18 1-888-992-3836 Free Membership Login. SOUTH SAN FRANCISCO, Calif., Nov. 12, 2021 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a cardio-metabolic biotechnology company developing transformational treatments for non-alcoholic steatohepatitis (NASH), today reported third quarter financial results for the period ending September 30, 2021. Akero Therapeutics Doses First Patient in Expansion of Phase 2a Trial in NASH. About Akero Therapeutics, Inc. 601 GATEWAY BOULEVARD SUITE 350, SOUTH SAN FRANCISCO, California, 94080, United States +1 650 487-6488. Akero Therapeutics Inc gets a 81 rank in the Biotechnology industry. EFX is currently being evaluated in two Phase 2b clinical trials: the HARMONY study in patients with F2/F3 advanced fibrosis and the SYMMETRY study in cirrhotic (F4) patients. Follows Akero’s first quarter announcement of topline results from a 30-patient expansion cohort of the. Published analysis showed that pre-cirrhotic NASH patients treated for 16 weeks with EFX achieved substantial reductions in liver fat, associated with decreases in markers of liver injury and inflammation, and reversal of fibrosis. In this second edition of Douglas Green's essential book on cell death, Green retains the bottom-up approach of the first edition, starting with the enzymes that carry out the execution (caspases) and their cellular targets before examining ... BRIEF-Akero Therapeutics Reports Q4 Loss Per Share $0.55 In this book, you will discover how to: Take stock of your experiences to ensure strategic career moves Discover how to cultivate and maintain fruitful relationships that support career growth Uncover how to build a two-year career strategy ... We look forward to working closely with the FDA to bring this promising investigational therapy to NASH patients as expediently as possible.”.
Learn about the media coverage comparison.
Akero’s investigational drug product candidate, efruxifermin (EFX) is a differentiated Fc-FGF21 fusion protein that has been engineered to mimic the balanced biological activity profile of native FGF21, an endogenous hormone that alleviates cellular stress and regulates metabolism throughout the body. By Seeking Alpha - Aug 13, 2021. Enabling power: European Union (Withdrawal) Act 2018, s. 8 (1). Akero Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Update. The FDA’s decision to grant EFX Fast Track designation follows recent clinical milestones highlighting EFX’s potential to address multiple drivers of NASH and reverse fibrosis. The second part of the book gives an overview of privileged cyclic small molecules and major classes of natural product-derived small molecules, including carbohydrate-derived compounds, peptides and peptidomimetics, and alkaloid-inspired ... This is no ordinary book on Grief. We're looking for talented individuals driven to make a difference for patients. We cover the latest Akero Therapeutics headlines and breaking news impacting Akero Therapeutics stock performance. Export data to Excel for your own analysis. Harrison covers the Healthcare sector, focusing on stocks .
Provided by GlobeNewswire Sep 7, 2021 5:00 AM PDT. Latest news headlines for Akero Therapeutics Inc with market analysis and analyst commentary.
Animal Models in Diabetes Research Akero Therapeutics Inc News (AKRO) - Investing.com Akero Therapeutics Inc - AKRO stock news - Page 4. Along with the history of their discovery in 1945, the analysis of the main texts that form this collection, the exposition of their most important beliefs, and the reasons for their suppression in the 4th century CE, you will learn about ... Start Your Risk-Free Trial Subscription Here, VMWare Stock Outlook: Cloudy With a Decent Chance For Growth, Consumer spending rebounds despite rising October inflation, Closing prices for crude oil, gold and other commodities, Putin tests experimental nasal vaccine against COVID-19, US stocks wobble; Gap, Nordstrom sink on weak results, Global stocks mixed after Fed says ready to act on inflation. Akero Therapeutics | EFX for NASH | Metabolic Disease | Home The Weight of Memory No news for in the past two years. ET News Corp is a global, diversified media . The stock was trading 9.6% higher, at the time of writing, in early trade on Wednesday. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Akero Therapeutics Company Profile - Office Locations ... Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. New Stories. Receive a free world-class investing education from MarketBeat. Get daily stock ideas top-performing Wall Street analysts. Nov 12, 2021 Aulos Bioscience Presents Preclinical Data Demonstrating Anti-Tumor Activity of AU-007, a Novel IL-2 Therapeutic, at 36th Society for Immunotherapy of Cancer (SITC) Annual Meeting. Akero Therapeutics - AKRO - Stock Price Today - Zacks This landmark volume discusses the characteristics and impact of the remodeling process on airway function and clinical disease expression within the airway in asthma, covering pharmacological therapies and possible future targets relevant ... This book takes a clinical approach to the patient with a genetic disease that affects the eye. Akero Therapeutics is a clinical-stage cardio-metabolic company developing transformational treatments for non-alcoholic steatohepatitis (NASH), a disease without any approved therapies. Akero is headquartered in South San Francisco. EFX is currently being evaluated in two Phase 2b clinical trials: the HARMONY study in pre-cirrhotic patients with F2/F3 fibrosis and the SYMMETRY study in cirrhotic (F4) patients.
To see all exchange delays and terms of use please see disclaimer.
Find the latest Akero Therapeutics, Inc. (AKRO) stock quote, history, news and other vital information to help you with your stock trading and investing. SOUTH SAN FRANCISCO, Calif., July 6, 2020 /PRNewswire/ -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a cardio-metabolic non-alcoholic steatohepatitis (NASH) company developing pioneering medicines designed to restore metabolic balance and improve the overall health of NASH .
October 19, 2021. Akero Therapeutics to Present at the Morgan Stanley Virtual Global .
SAN FRANCISCO, Aug. 12, 2020 /PRNewswire/ -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a cardio-metabolic non-alcoholic steatohepatitis (NASH) company developing pioneering medicines designed to . Biotechnology is number 88 out of 148 industries. Compare. Akero Therapeutics Inc gets a 84 rank in the Biotechnology industry. Risks that contribute to the uncertain nature of the forward-looking statements include: risks related to the impact of COVID-19 on Akero's ongoing and future operations, including potential negative impacts on Akero’s employees, third-parties, manufacturers, supply chain and production as well as on global economies and financial markets; the success, cost, and timing of Akero's product candidate development activities and planned clinical trials; Akero's ability to execute on its strategy; positive results from a clinical study may not necessarily be predictive of the results of future or ongoing clinical studies; regulatory developments in the United States and foreign countries; Akero's ability to fund operations; as well as those risks and uncertainties set forth more fully under the caption "Risk Factors" in Akero’s most recent Annual Report on Form 10-K, as filed with the Securities and Exchange Commission (SEC) and quarterly reports on Form 10-Q filed with the SEC, as well as discussions of potential risks, uncertainties and other important factors in Akero’s other filings and reports with the SEC. Free real-time prices, trades, and chat.
Akero Therapeutics Receives FDA Fast Track Designation for Efruxifermin (EFX) for the Treatment of NASH. What Makes Akero Therapeutics, Inc. (AKRO) a New Buy Stock. Can Fintech Affirm Holdings Rebound After Recent Skid? Free real-time prices, trades, and chat. 07:23a: Akero Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business U.. PU.
Please log in to your account or sign up in order to add this asset to your watchlist. Assets. In July, Nature Medicine published full results of the main portion of Akero’s Phase 2a BALANCED trial in biopsy-confirmed NASH patients with F1-F3 fibrosis—the first published clinical evidence of fibrosis regression with an FGF21 analog. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: You have already added five stocks to your watchlist. Akero Therapeutics, Inc. operates as a cardio-metabolic nonalcoholic steatohepatitis company, which engages in developing pioneering medicines designed to restore metabolic balance and improve . Did You Forget to Ask these 8 Money Questions During College Visits?
Akero Therapeutics is advancing new medicines designed to treat serious metabolic diseases by restoring metabolic balance. Akero Therapeutics news and AKRO price. During the second quarter, Akero continued to enroll patients in the HARMONY study, a Phase 2b multicenter, randomized, double-blind, placebo-controlled, clinical trial in biopsy-confirmed pre-cirrhotic NASH patients (fibrosis stages F2 and F3).
MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Today's Range $24.58 $26.24. Akero Therapeutics has a market capitalisation of US$773m and burnt through US$75m last year, which is 9.8% of the company's market value. In July, Akero initiated its SYMMETRY study, a Phase 2b, multicenter, randomized, double-blind, placebo-controlled, clinical trial in biopsy-confirmed NASH patients with compensated cirrhosis (F4), Child-Pugh class A. MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Visit us at www.akerotx.com for more information.
Fastest German Players Fifa 21, Cedar Grove Elementary School Yearbook, Michail Antonio Injury, Set Of Assorted Greeting Cards, Shower Curtains With Accessories, Isthmian League Fixtures 2021/22, Ethiopian Potato Stew,